For patients with driver mutations, such as EGFR (10% of NSCLC cases) and BRAF (0.5–4.9% of lung adenocarcinomas), and rearrangements in ROS1 (1–2% of lung adenocarcinomas) and ALK (3–7% of lung adenocarcinomas) gene-targeted therapy can be used [6,7]. This evidence concerns the gene ROS1 and lung adenocarcinoma.